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Abstract: 
αβT cells have a wide distribution of their CD3 membrane density. The aim of this paper was 
to evaluate the significance of the CD3 differential expression on T cell subsets. Analysis was 
performed on healthy donors and renal transplant patients by flowcytometry The results 
obtained are :  
 CD3 expression was widely distributed (CV =38.3±3.1 to (43±2.3%). 
 The CD4, CD8,CD45 and forward scatter were similarly distributed. 
 The diversity of CD3 expression was direcly related to the clonotypes: γ9, non γ9 from 
γδT cells and Vβ clonotype from αβT cells (e.g.: Vβ3FITC 7980±1628 Vβ8PE: Vβ20-
FITC 11768±1510). 
 Using a computer simulation, we could confirm differential kinetics of T cell activation 
according to the initial parameters. Finally, in vitro activation was significantly higher 
on Vβ8 and Vβ9 (high CD3) compared to Vβ2 and Vβ3 (low CD3, P=0.040 to 0.0003). 
In conclusion: T cells have highly heterogeneous CD3 expression, possibly predetermined and 
with clear functional significance. 
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Abbreviations : 
APC Artificial presenting Cell. 
Cy Cyanine 
EDTA EthyleneDiamineTetraAcetic Acid 
FCM Flow cytometry 
FITC Fluorescein IsoThioCyanate 
MdFCS Median Forward Scatter 
MdFI median fluorescence intensity 
MdFCS Median Forward Scatter 
PE Phyco-Erythrin 
TCR T cell receptor 
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I. Introduction  
During immunization, the T cell receptor (TCR) bind specifically to the peptide-MHC complex 
if their avidity is appropriate [1-6]. The binding is strengthened by coreceptors, such as, CD4 
or CD8 [7-9]. Signal transduction is carried through CD3 that is physically associated to TCR 
[10]. The CD3-TCR complex is then internalized inducing a significant decrease of membrane 
CD3/TCR expression and partial activation leads to non responsiveness status until the 
membrane level of CD3 is restored. [11-14]. A minimal number of TCR/CD3 engagement is 
required for efficient induction of T cell activation [15-17]. If the number of p-MHC is 
restricted, serial engagement of TCR are possible [18-20]. Further TCR/CD3 complexes need 
to be  recruited from outside the synapse through surface transfer but this has to be 
completed during a short lag time [16, 21-23] to be efficient. Activation induce IL-2 
production and membrane expression of the γ chain of its receptor (CD25;   [24]). Il2 binds to 
the receptor, induces signal and is internalized for subsequent steps of T cell activation. 
Membrane CD25 expression is correlated with T cell activation [25].  
 
Experimental data have demonstrated that a number of CD3-TCR is crucial for T cell 
reactivity. It is thought that the starting membrane density is similar between individual T 
cells. These processes have been mimicked by computational models [26-29] and compared 
with published data using well described peptides [6]. IL2-IL2R complex is rapidly produced 
up to a peak (zenith) before exponential decline. Testing peptides with different avidity have 
shown that the delay and height of the simulation peak directly reflects of the cell capacity for 
anergy or proliferation [26]. 
 
It has been recently shown that CD3 membrane density could be heterogeneously distributed 
on T cell subsets with a bimodal distribution. Indeed, γδT cells do express higher levels of 
CD3 than αβT cells [30-33]. But CD3bright T cells do not include all γδT cells. Peripheral γδ T 
cells have restricted diversity. In healthy donors, the γ9 clonotype is almost exclusively 
present in blood though in other circumstances, different γδ isotypes are present in blood [34-
36] and express lower CD3 levels. Looking more closely, αβT cells themselves appear to have 
a wide distribution of their CD3 membrane density and their size.  This should theoretically 
influence their capacity to respond [26].  
 
The aim of this paper was to approach the significance of the differential expression of CD3 on 
αβT cells observed in healthy donors and immuno-compromised patients. 
I.1. Patients and methods  
Lymphocyte analysis was performed on samples from 97 healthy adult blood donors and 56 
consecutive samples from renal transplant patients, (time from graft 1-15 years). For 
regulatory reasons, Blood donor sample could only be tested the day after withdrawal, 
whereas patient samples were tested fresh, within 6 hours of withdrawal. Functional tests 
were performed on 10 fresh samples from patients from the cardiology department without 
immune defect (patients with non severe vascular diseases). 
 
Lymphocytes were immunolabeled in routine practice using a combination of: CD3-
Fluorescein IsoThiocyanate (FITC, IgG1, clone sk7),  CD16-Phycoerythrin (PE, IgG1, Clone 
B73.1), CD56-PE (IgG1, Clone NCAM 16.2), CD45-Peridin Chlorophyl Protein (PerCP, IgG1, 
clone 2D1),  CD4-PE-Cyanin7 (PE-Cy7, IgG1, clone SK3),  CD19-Allophycocyanin (APC, IgG1, 
clone SJ25C1), and  CD8-APC-Cyanin7 (APC-Cy7, IgG1, clone SK1). An alternative labelling 
was used for γδT cell analysis using: CD3-APC-Cyanine 7 (clone sk7), all from BD Biosciences 
(San Jose, CA) and CD8α-APC (clone SFCI21thyD3), CD4-PE-Cy7 (clone SFCI12T4D11), 
CD8β PE-Cy5 (clone 2ST8.5H7) and even TCRγ/δ FITC (clone Immu 510) or TCRγ9 (Immu 
360) all from Beckman-Coulter; Fullerton, CA. 
 
The clonotypes of TCR V beta chain were identified using pairs of conjugated monoclonal 
antibodies to: Vβ1 (clone BL37.2) PE and Vβ2 (clone MPB2D5) FITC, Vβ3 (clone CH92) FITC 
and Vβ4 (clone WJF24) PE, Vβ5.1 (clone IMMU157) FITC and Vβ5.3 (clone 3D11) PE, Vβ5.2 
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(clone 36213) FITC and Vβ8 (8.1 and 8.2; clone 56C5) PE, Vβ7 (clone ZOE) FITC and Vβ9 
(clone FIN9) PE, Vβ11 (clone C21) PE and Vβ12 (clone VER2.32.1) FITC, Vβ13.1 (clone 
IMMU222) PE and Vβ13.6 (clone JU-74) FITC, Vβ14 (clone CAS1.1.3) PE and Vβ16 (clone 
TAMAYA 1.2) FITC, Vβ17 (clone E17.5F3) FITC and Vβ18 (clone BA62) PE, Vβ20 (clone ELL 
1.4) FITC and Vβ22 (clone IMMU 546) PE, Vβ21.3 (clone IG125) FITC and Vβ23 (clone AF23) 
PE (all purchased from Beckman-Coulter). All associated with CD3-APC-Cy7, CD8α-APC, 
CD4-PE-Cy7, CD8β PE-Cy5. 
 
For the activation test, fresh density gradient isolated mononuclear cells (PBMC) were 
incubated for 30 h with CD3/CD28 coated beads (Dynal; Norway) at approximately equal 
number according to manufacturer instructions. After incubation, cells from the same well 
were washed and labeled with three combinations of representative clonotype: Vβ1 PE/Vβ20 
FITC; Vβ2 FITC/Vβ8 PE and Vβ3 FITC/Vβ9 PE, associated with CD3-APC-Cy 7, CD8α-APC, 
CD4-PE-Cy7, CD25 PE-Cy5 (Clone MA251; BD Biosciences). 
 
The absolute membrane density of receptors was evaluated by indirect labeling, using 
commercially available QuiFiKit® (Dako Denmark) according to the manufacturer 
instructions. 
 
The immunolabeling procedures were performed on 100μL of EthyleneDiamineTetraAcetic 
Acid (EDTA) anti-coagulated fresh peripheral blood, incubated with 10 to 20 μL of antibody, 
gently mixed and incubated for 20 min at room temperature in the dark. The lysis and 
fixation were obtained by adding 500µL of FACSLysing solution™ (BD Biosciences). Samples 
were analyzed within 1 h on a FACScanto II (BD Biosciences). For Vbeta labeling, erythrolysis 
was performed using Versalyse® solution (Beckman-Coulter) and samples were washed with 
4ml Phosphate buffer before analysis.  
 
Instrument setting were performed on nine tubes (unlabeled, six single labelled, six isotype 
controls, and the mixed antibodies) using FACS Diva™ calculation facilities (BD Biosciences) 
as previously described [37]. Instrument settings were daily checked using standardized (7 
color Setup beads). Blood analysing is daily validated using external quality control (Multi-
check control; BD Biosciences).  
 
Dot plots were analyzed using FACS Diva™ (BD Biosciences): CD3 versus side scatter 
identification. CD4+ and CD8+ were analyzed on CD3+. Vbeta clonotypes were analysed on 
30, 000 T cell events, on either CD3+CD4+CD8- or CD3+CD4-CD8+ lymphocytes. The γδT 
cells were defined on CD3/γδTCR. γ9 positive cells were determined on γδTCR + T cells. CD4 
or CD8 were determined on CD3+/γδTCR negative cells.  
 
The cell size was estimated from forward scatter according to Sloot et al. and Symianov et al. 
[38, 39]. In absence of bead that are standardized for the size, we used commercially available 
beads with different sizes as described by individual manufacturers: Flowcount® beads 
(10µm; Beckman-Coulter), QIFIKIT® beads (10µm, Dako); 7 color setup® beads ( 4 and 
6µm, BD Bioscience), Trucount® beads ( 4 µm, BD Bioscience), Rainbow® beads (3 - 3.4µm, 
BD Bioscience). The cell sizes were analyzed by electronic microscopy. Briefly, beads were 
washed in distilled water, treated with cacodylate 0.2M and washed in progressive 
concentration of ethanol up to 100% before complete desiccation. Samples were then 
sputtered with gold-palladium coating and analyzed with scanning electron microscope 
(JEOL 840). More than 25 beads were measured manually on photographs. The reflection 
index was evaluated at 1.592 for polystyrene beads and 1.456 (Nucleus) and 1.355 (Cytoplasm) 
for T cell. The size of the nucleus was estimated at 80% of the cell size according to the 
literature [38]. The bead and cell volumes were calculated from measured FSC peak height 
according to Mie’s theory for spherical multilayer particles optics. 
Statistical analysis was performed using, paired Student’s t-test for comparison of two cell 
sub-populations from the sample, linear regressions and expressed as median ± 1SD. 
Coefficient of variation (CV) were calculated as 1SD/mean. 
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Because the fluorescence intensity did not always have a normal distribution, we chose to 
consider the median (MdFI) instead of the mean fluorescence intensity (MFI). MdFI and each 
sample CV were calculated automatically by the FacsDiva software. 
II. Results 
II.1 Wide heterogeneity of CD3 expression inside T cell subsets: 
In routine blood T cell analysis, we observed a wide distribution of CD3 expression on T cells 
(Figure 1a). We have confirmed this interindividual cell diversity in 96 healthy donors: the 
MdFI was 1100±178 on CD8+ T cells meaning a 16.1% coefficient of variation (CV) between 
donors. 
 
Figure 1: High variability of CD3 FITC fluorescence intensity observed on CD3FITC/CD56 
PE/CD4PE-Cy7/CD19APC/CD8APC-PE-Cy7/CD45PerCP routine lymphocyte analysis (one 
representative case; panel a). CD3 expression was higher on CD4+ T cells compared to CD8 (panels b 
& c). 
The CD3 expression was significantly (P<0.0001) higher on CD4+ T cells (1,401 ±248) with 
similar CV (17.7%; Figures 1b and 1c). However, what was more intriguing was the wide 
variation between cells inside each sample (intraindividual) CV: 38.3±3.1% for CD8+ T cells 
and 43±2.3% for CD4+ T cells (Figure 1b). A similar discrepancy was observed on 56 
consecutive patients (intraindividual CV: 32.7±2.7%; on CD8+ and 37.0±2.3% on CD4+ T 
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cells). The discrepancy of CD3 expression was confirmed with an alternative anti-body 
combination that included CD3 APC-Cy7, CD8 APC, CD4 PE-Cy7: CVs =  27.8±6.4% on CD8+ 
and 34.4±6.7% on CD4+ T cells (n= 40 patients). 
II.2.The IntraIndividual Variability was Repeatedly Observed in all T Cell Isotypes:  
There is good evidence that CD3 expression differs amongst some T cell subtypes particularly 
αβ or γδ TCRs. We could confirm that CD3 levels were significantly higher on γ9 γδT cells 
(MdFI: 17,933 ±3 214 in 40 patients) compared with conventional T cells (paired t-test:  
P = 0.0001). Similar to the conventional T cells, the CD3 expression was highly heterogeneous 
on γ9 γδT cells (mean of individual CVs: 36.6±8.0% Figure 2a). Conversely, the CD3 
expression was not so high on “non-γ9” γδT cells (14,005 ±4 386 compared to γ9 γδT cells ;  
P = 0.0001) but still significantly higher than on αβT cells (P =0.0187) and large individual 
CVs: 36.4±9.5%. 
 
Figure 2: CD3 APC-Cy7, CD8 APC, CD4 PE-Cy7 and γδ FITC were tested on 40 patients. CD3 
expression was widely distributed on classical γ9 peripheral γδT and higher compared to αβ (panel 
a). Some patients had an additional non γ9 population of γδT cells (panel b) with even wider 
distribution of CD3. The two γδ populations had significantly higher CD3 expression  compared to 
CD4+ and CD8+ αβ T cells (panel c). 
In the same experiment, we have compared the levels of CD3 expression on CD4+ and CD8+ 
T cell after exclusion of γδT cells that partially express CD8. Again, we observed that the CD3 
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APC-Cy7 expression was higher on CD4-PE-Cy7+ (MdFI: 13,535 ±2 020) than on CD8-APC+ 
αβ T cells (MdFI: 11,435 ±1 717; P < 0.0001; Figure 2c). Because possible artifacts could be 
due to the spectral overlap compensations between the CD8 APC and the CD3 APC-Cy7 
signals, we have confirmed the difference of CD3 expression between CD4+ and CD4- αβT 
cells in five patients using the same labeling combination except CD8 APC (“fluorescence-
minus-One” procedure; results not shown). 
II.3.Were There Differences of CD3 Expression Between TCR Vβ Clonotypes? 
Because CD3 levels of expression varied between γδ clonotypes, we investigated also differed 
between αβ clonotypes.  
 
Figure 3: CD3 APC-Cy7, CD8 APC, CD4 PE-Cy7, and Vβ clonoctype FITC/PE were tested on 28 
healthy donors. CD3 median fluorescence intensity (MdFI) was reproducibly different according to 
the clonotype of the cells. Values were always higher on CD4+ (upper) than CD8 T cells (lower panel) 
T cells. 
Using CD3 APC-Cy7, CD8 APC, CD4 PE-Cy7, and two anti Vβ clonotypes conjugated with 
either FITC or PE in 28 healthy blood donors, we observed consistent differences of CD3 
expression according to the Vβ clonotype (Figure 3). MdFI were repeatedly very low on some 
clonotypes (e.g. for CD4+ T cells: Vβ1 PE: 7,366 ±1,236; Vβ2 FITC 8,023 ±1,140, Vβ3 FITC 
7,980 ±1,628) and very high (paired t-test: P <0.0001) in few other clonotypes: (e.g.: Vβ8 PE: 
12,845 ±1,695; Vβ9 PE 12,435 ±2,093; Vβ20-FITC 11,768 ±1510). In accordance with the first 
experiments, the CD3 expression was always higher on CD4+ than on CD8+ T cells but the 
differences between the clonotypes were the same for the CD4+ cells (Figure 3 upper panel) 
and the CD8+ T cells (Figure 3 lower panel). The differences were repeatedly observed in all 
patients and were not related to the fluorochrom (PE or FITC) used for the anti-clonotype 
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conjugates: on clonotypes that were labeled with either FITC or PE, the CD3 was low (e.g. anti 
Vβ1-PE or anti Vβ2-FITC) or high (e.g. anti Vβ3-FITC or Vβ20-PE) (see Figure 3). 
II.4.Was the Variability of Expression Restricted to CD3? 
If CD3 expression had wide variability in each samples, we also observed high variability of 
expression of other membrane receptors: CD45: 6,269 ±893 (CV = 14.2%) on CD4+ T cells 
and 7,976 ±1,186 (CV = 14.9%) on CD8+ T cells; CD4: 7,159 ±755 (CV = 10.5%) on CD4+ T 
cells and CD8: 12,054 ±1,518 (CV = 12.6%) on CD8+ T cells in 56 consecutive patients.  
 
 
Figure 4: CD3FITC/CD56 PE/CD4PE-Cy7/CD19APC/CD8APC-PE-Cy7/CD45PerCP was analyzed on 
56 consecutive patients. The levels of CD4 or CD8; CD45 (left scale) and forward scatter (FSC; right 
scale) were analysed on CD4+ (upper panel) or CD8+ (lower panel) according to the level of CD3 
arbitrarily divided in 8 equidistant sections (insert). CD4 and partly CD8, FSC increased with CD3 
expression suggesting a cell size effect. 
To compare the level of two receptors, we have arbitrarily divided the T cell population in 
eight equidistant sections on the logarithmic scale of CD3 fluorescence intensity (Figure 4, 
insert). We then compared CD4 or CD8 and CD45 levels of expression between these CD3 
sections. The CD4 gradually increased with CD3 levels (P <0.001, paired t tests between two 
consecutive CD3 levels sections). The CD8 also gradually increased in all but the highest 
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sections (P <0.001). Similarly, the CD45 gradually increased on CD8+ T cells (P = 0.001) but 
only in the first five sections of CD4+ T cells (P < 0.026). 
II.5.Was the Difference of Expression Due to Size Diversity of the Cells? 
Because the levels of expression of all receptors tested were varying in the same way, we 
wanted to know if it was related to differences in sizes. The median of forward scattering 
intensity (high of the peak: MdFSC-H) gradually increased with the level of CD3 (Figure 4) on 
CD4 + T cells (upper panel) and CD8 + T cells (lower panel, P <0.0001 on paired t-test for 
each sections compared to the previous one with lower CD3 level).  
 
Figure 5: Relationship between forward scatter and particle size a) on beads with different size 
measured by scanning electronic mMicroscope; b) Cell surface calculated from forward scatter 
according to the level of CD3 arbitrarily divided in equidistant sections in 56 consecutive patients; c) 
direct CD3 intensity / FSH ratio on individual cell sizes in the CD3 sections in 14 consecutive patients. 
To estimate the cell sizes from the MdFSC, we have first determined the size of some setting 
beads that could be used as standards, by scanning electronic microscopy (Figure 5a). The 
bead diameters were: 8.35 ± 0.32µm for the Qifikit® beads (n=34); 3.22±0.089 (n=25) and 
4.48 ± 0.16µm for the 7-color setup® beads (n=48); 2.49 ±0.89 µm for the Trucount® beads 
(n=37); 8.60 ±0.22µm for the Flowcount® beads (n=31) and 27.8±2.8 µm for the Rainbow® 
beads (n=75). We then analyzed their FSC-H (five repeats), using the same settings as the one 
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used for the cell analysis. We could confirm that the bead MdFSC-H were directly correlated 
to the bead size in a linear relation) y = 7382.5x - 5671.7; r² = 0.996 (Figure 5).  
According to the Mie’s theory and reflection index of cells, we could estimate the cell size 
(diameter, d) with the function: [FHS-H = 1250 d²] showing that the FSC-H was proportional 
to the cell surface rather than their diameter. 
Accordingly, we have analyzed, the mean cell diameter of cells was 11.1 µm for LyT CD4+ and 
11.5 µm for CD8+ T cells in the 56 consecutive samples. Interestingly, the cell sizes 
progressively increased with levels of CD3 from 10.5 to 11.6 for CD4+ and 10.5 to 12.2 for 
CD8+ T cell (Figure 5b). In another test, we have considered the CD3 / FSC-H ratio measured 
individually on each cell during analysis of 14 consecutive the samples. The ratio progressively 
rose with the level of CD3, from 853 ± 163 to 3,843 +/-523 for CD4+ T cell and 829 ±144 to 
3,314 ± 303 for CD8+ T cells (Figure 5c) confirming the close relationship between the level of 
CD3 expression and the cell size.  
However, CD3 fluorescence intensities rose more than the cell size (Figure 5b). This suggests 
that the differences in size were not sufficient to explain the large variability of CD3 
expression and larger cells did indeed express high surface density of CD3, especially on 
CD8+ T cells.  
II.6.Could the CD3 Differential Expression Have Functional Consequences? 
Because the number of CD3, as part of the TCR complex, is crucial threshold for T cell 
activation after specific peptide recognition, we investigated whether differences in expression 
could influence the T cell reactivity. We simulated the kinetic effect of the size or CD3 density 
on the cell activation using a mathematical simulation, we have recently published [26], and 
also first estimated the absolute CD3 expression on lymphocytes using the Qifikit® system, in 
39 healthy donors. The level of CD3 was 61,050±25,346 molecules per cell corresponding to 
30,525±12,623 TCR/Cell. Thus, we compared the activation kinetics for CD3 levels from 
50,000 to 70,000 CD3 mol/cell for one given peptide. For a given size, the simulations have 
shown that the T cells with higher levels of membrane CD3 reached higher levels of activation 
(zenith of the peak, Figure 6a). On the other hand, for each CD3 level, the cell size had little 
effect on the height of the peak (capacity of response) but smaller cells reached more rapid 
activation (reduced the time-lap) for achieving the zenith of the peak (Figure 6b). Overall, the 
level of CD3 expression had a predominant influence on activation triggering whatever the 
size of the cells was. 
We then checked that hypothesis experimentally, in an in vitro activation model in 13 healthy 
donors using anti-CD3-CD28 beads that guaranteed equal activation for all T cells. The 
activation was measured through the induction of Il-2 receptor (CD25) after 30 h, on few Vβ 
clonotypes with extreme CD3 levels. The CD4+ T cells (Figure 7 left column) were 
significantly more activated than CD8+ T cells (Figure 7 right column) that expressed lower 
levels of CD3. Furthermore, the activation was more efficient on clonotypes that were 
associated with high levels of CD3 high (Vβ8 and Vβ9) compared to CD3 low clonotypes (Vβ2 
and Vβ3; P=0.040 to P=0.0003). The difference was not significant on CD8 Vβ1/Vβ20 and 
CD4 Vβ2/Vβ8 and even reversed in one case (CD4+: the Vβ1 cells were more reactive than 
Vβ20 cells: P=0.007). 
III. Discussion 
T cells are usually considered as a homogenous group of cells with similar properties and 
generally characterized by the mean or median of the whole population neglecting the 
population variability. The T cells have been separated in two main subsets CD4 / CD8 and 
more minor subsets such as γδT, Th1/Th2, regulatory or Th17 T cells but this was only 
considered on the quality of their functions. The dynamics of the T cell activation is generally 
considered as similar for all T cells of any subtypes. In this study, we have focused on the large 
diversity of T cells within any individual sample in terms of membrane expression of their 
receptors. We observed that variability was constant among healthy donors as well as among 
patients with immune disorders. It cannot be attributed to experimental error or variation as 
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instruments have very narrow signal CV (<2%) when standardized quality assurance beads 
were tested [37]. 
 
Figure 6: In silico simulation of the T cell activation kinetic for different initial CD3/TCR densities 
(25-35 000 CD3-TCR complexes per cell) and cell sizes (radius 2.5 to 3.5µm). Activation induced IL-2 
and its receptor production. IL-2 binds to its receptor. The complex internalization is considered as 
the decision parameter for entry in cell cycle. The peak height is the major parameter reflecting the 
intensity / optimal time for T cell activation as it could be checked using data from ago-antagonist 
peptides. CD3 level was related to the intensity of the signal while cell size was related to the time 
delay. 
It cannot be due to technical factors as the cells were prepared in the same way, in the same 
tube, with the same reagents and the individual cells were compared within the same sample, 
with the same labeling. Furthermore, the differences were very reproducible between 
different samples.  
The T cell diversity we have observed was large enough to have functional significance. 
Indeed, it has been largely demonstrated [3-5, 10, 15, 17, 20] that the specific T cell activation 
is directly dependent on the amount of antigens, the amount of TCRs and there mutual 
affinity. As soon as the T cell has recognized its specific peptide, the TCR-CD3 involved in the 
binding are activated and internalized. 
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Figure 7: Fresh peripheral blood mononuclear cell from 13 blood donor were activated with CD3-
CD28 beads for 30 h. The activation level was measured using CD25 PE-Cy5 on CD3 APC-Cy7, CD4 
PE-Cy7 and CD8 APC T cells for the different clonotypes: Vβ1PE/Vβ20FITC; Vβ2FITC/Vβ8PE and 
Vβ3FITC/Vβ9PE.  These clonotypes were chosen for their extreme CD3 levels of expression: Vβ1 
(7,366+1,236 / 5,857+841); Vβ2 (8,023 +1,140 / 7,368 + 886); Vβ3 (7,980 +1,628 / 6,947 +1,315); Vβ8 
(12,845 +1,695 / 10,457 +1,732); Vβ9 (12,435 +2,093 / 10,430 +1,568); and Vβ20 (11,768 +1,510 / 
9,870 +1,174) on CD4/CD8 respectively.  
A minimal number of TCR need to be activated to reach the level of activation that is 
sufficient to make the decision for the cell function and fate (either proliferation, or anergy or 
activation induced apoptosis).  
The number of p-MHC complexes presented by the dentritic cells is less critical because the 
TCR binding is very brief and several TCR can sequentially bind one single p-MHC complex 
(serial engagement). However, if the number of CD3-TCR inside the synapse is not sufficient, 
more are recruited from the outside the synapse. The surface transfer of the receptor takes 
time and the distance for the transfer rises with the cell size. Thus, the initial number of CD3 
certainly influences the speed of T cell specific activation. We tested this hypothesis using 
computer model we have developed recently [26]. This model was not completely achieved 
because many parameters that are involved in the activation process still need to be precisely 
determined. However, preliminary comparisons of the calculated data with experimental data 
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obtained from the literature [6, 19, 22, 23] have shown  that this model was realistic. In the 
present study, we have used this computer simulation choosing a set of initial parameters 
(agonistic peptide, cell sizes and CD3 levels of expression) that are close to the conditions in 
vivo. These simulations show that the initial number of CD3 available significantly influences 
activation in the same order of magnitude as the differences observed with agonistic and 
antagonistic peptides. We confirmed the functional significance of the initial level of CD3 
expression experimentally. T cells were challenged with an APC. Beads coated with anti-CD3 
and anti-CD28 should bind equally all T cells, regardless of the TCR structure or avidity for 
the p-MHC complex. Analysis the early activation effects (membrane CD3, CD25, CD69 
expression), during the first 30 h before first cell division because the levels of expression of 
receptors and the cell size cannot be simply compared between activated mother and new 
daughters. We compared different clonotypes within the same samples so the cell 
preparations were performed in the same conditions, in the same well in order to reduce any 
technical biases. Experimental artifacts were minimized because T cells were exposed 
randomly, and with equal probability, in the same environmental conditions (same well, same 
environment) to the most physiological in vitro polyclonal activation system (anti-CD3/anti-
CD28 on beads). Activation of each clonotype was compared in duplicate and with their 
unactivated homologs. The labeling should not interfere with the results and high / low CD3 
groups were tested with alternative FITC/PE combinations.  
 
The CD3 expression is related to the cell size but the relationship was not linear and cells with 
high FSC had much more CD3. This was confirm on comparison of FSC values between 
sections of increasing CD3 levels and confirmed by measuring the individual CD3/FSC ratio. 
The physical study of FSC reveals that FSC is directly related to the square diameter of the 
particles, that is, the cell surface. This allowed us to relate the CD3 expression to a surface 
density. The real cell surface can be calculated but we had many difficulties to count the 
absolute number of CD3 on different cell subsets. The Qifikit® is the best way to measure it 
but it uses an indirect labeling method that is not compatible with multiple color analysis. 
This could have been solved with sorting of different T cell subsets but it would have needed a 
CD3 labeling that make quantization impossible. 
 
There are physical arguments to explain a relationship between the level of CD3 available and 
T cell reactivity. A sufficient recruitment of CD3/TCR complex is needed in the synapse in 
order to reach a sufficient level of signal transduction [7, 12, 17-19, 40]. The number of p-
MHC has low limiting role because of possible serial engagement of different TCR on the 
same p-MHC complex [17-20]. The number of receptors in the synapse is not sufficient to 
reach that threshold and more molecules are needed from the rest of the membrane. The 
recruitment is due to membrane transfer of the molecule, at linear speed [13]. It is reasonable 
to consider this speed as constant for different cell types because it depends on membrane 
constituents and cytoskeleton motion that is considered common for all T cells. On larger 
cells, the molecule pool is larger (higher fluorescence intensity) but the transfer takes more 
time to reach the synapse. In the model, we have used medium cell sizes (radius from 2.5 to 
3.5 µm) and CD3 initial densities (50 to 70,000 CD3ε molecules corresponding to 25-35,000 
CD3/TCR complexes per cell) and a constant surface speed observed from published 
experiments [13]. Overall, our theoretical and experimental data have proved that CD3 
expression variability has functional implications. Opposite conclusions were raised regarding 
GPIIIB-IIIA molecular density that was not correlated to aggregability of L-platelets [41] In 
vitro activation of T cells was repeatedly more efficient on clonotypes with High CD3 levels 
compared with clonotypes with low CD3 levels. This was not unequivocal as all clonotypes 
were not tested and some clonotypes did not show significant differences. 
 
Is CD3 level variability related to cell fate? Intriguing but repeatedly confirmed, that CD3 
expression was significantly different on T cell subsets. Accordingly, CD4+ T cells (with higher 
CD3 expression) are more frequently activated in stimulation tests. The relationship with 
clonotypes was more surprising. The TCR design is a stochastic process that should not 
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interfere with the cell physiognomy. This discrepancy was already known for γδT cells but the 
ontogeny, the recognition skills and physiological role of theses cells are very different from 
conventional αβT cells. How could CD3 expression and activation potential be related to the 
clonotype? Because the Vβ segment is involved in binding p-MHC complexes, it is possible 
that the T cells adapt their CD3 level and size with their avidity for the MHC and / or ligand. T 
cells could use physical means for a better adaptation of its reactivity to the frequency or 
intensity of the challenges. On the other hand, considering that the clonotype determination 
is relatively hazardous for one given peptide/MHC complex, our results suggests some 
individual variability in the responsiveness to a given antigen according to which TCR 
clonotype is chosen. The clonotype related mechanism could be influenced by the MHC 
haplotype, the peptide itself and TCR avidity for the p-MHC complex. The other co-
stimulation molecules (CD4 or CD8, CD28, …) should not strongly interfere because they are 
common to all cells. Regarding to cytometry data interpretation, membrane density of 
receptor on cell surface deserves attention because of possible functional significance but one 
must consider that an increase of mean fluorescence intensity of a cell population does not 
necessarily mean that surface density is increased on all individual cells [42]. 
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